Want to see ABUS full AI Analyst Report?
Arbutus Biopharma (ABUS) Ratios
1,286 Followers
Arbutus Biopharma Ratios
ABUS's free cash flow for Q2 2026 was $-6.02M. For the 2026 fiscal year, ABUS's free cash flow was increased by $0.00 and operating cash flow was $-6.02M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 15.73 | 8.15 | 5.87 | 4.60 | 14.32 |
| Quick Ratio | 15.73 | 8.15 | 5.87 | 4.60 | 14.32 |
| Cash Ratio | 3.00 | 2.33 | 1.17 | 0.94 | 9.74 |
| Solvency Ratio | -1.84 | -2.00 | -1.86 | -1.16 | -2.13 |
| Operating Cash Flow Ratio | -6.60 | -4.15 | -3.82 | -1.08 | -6.02 |
| Short-Term Operating Cash Flow Coverage | -72.46 | 0.00 | 0.00 | -95.04 | 0.00 |
| Net Current Asset Value | $ 76.41M | $ 92.97M | $ 93.64M | $ 92.57M | $ 125.61M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.04 | 0.05 | 0.06 | 0.06 | 0.09 |
| Debt-to-Equity Ratio | 0.05 | 0.06 | 0.08 | 0.09 | 0.11 |
| Debt-to-Capital Ratio | 0.05 | 0.06 | 0.08 | 0.08 | 0.10 |
| Long-Term Debt-to-Capital Ratio | 0.04 | 0.05 | 0.06 | 0.07 | 0.09 |
| Financial Leverage Ratio | 1.24 | 1.35 | 1.36 | 1.43 | 1.21 |
| Debt Service Coverage Ratio | -51.31 | -499.29 | -154.65 | -31.60 | -25.07 |
| Interest Coverage Ratio | -278.88 | -557.07 | -170.16 | -37.92 | -25.73 |
| Debt to Market Cap | 0.00 | 0.01 | 0.02 | 0.03 | 0.04 |
| Interest Debt Per Share | 0.02 | 0.03 | 0.06 | 0.09 | 0.20 |
| Net Debt to EBITDA | 0.42 | 0.44 | 0.25 | 0.29 | 1.26 |
| Profitability Margins | |||||
| Gross Profit Margin | 97.42% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -237.19% | -1130.82% | -399.04% | -162.19% | -667.91% |
| EBITDA Margin | -234.62% | -1108.46% | -391.30% | -158.54% | -651.96% |
| Operating Profit Margin | -192.08% | -1236.74% | -430.53% | -167.75% | -669.11% |
| Pretax Profit Margin | -237.88% | -1133.04% | -401.57% | -166.62% | -693.91% |
| Net Profit Margin | -237.88% | -1133.04% | -401.57% | -178.01% | -693.91% |
| Continuous Operations Profit Margin | -237.88% | -1133.04% | -401.57% | -178.01% | -693.91% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 106.84% | 100.00% |
| EBT Per EBIT | 123.84% | 91.62% | 93.27% | 99.32% | 103.71% |
| Return on Assets (ROA) | -35.41% | -53.09% | -50.45% | -35.54% | -37.29% |
| Return on Equity (ROE) | -43.75% | -71.81% | -68.71% | -50.75% | -45.00% |
| Return on Capital Employed (ROCE) | -30.53% | -65.74% | -64.06% | -40.27% | -38.04% |
| Return on Invested Capital (ROIC) | -30.34% | -65.47% | -63.84% | -40.17% | -37.97% |
| Return on Tangible Assets | -35.41% | -53.09% | -50.45% | -35.54% | -37.29% |
| Earnings Yield | -3.64% | -11.52% | -17.56% | -19.75% | -18.45% |
| Efficiency Ratios | |||||
| Receivables Turnover | 8.06 | 2.56 | 10.21 | 28.86 | 12.22 |
| Payables Turnover | 0.31 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 440.09 | 1.42 | 2.98 | 5.73 | 1.36 |
| Asset Turnover | 0.15 | 0.05 | 0.13 | 0.20 | 0.05 |
| Working Capital Turnover Ratio | 0.14 | 0.06 | 0.16 | 0.29 | 0.08 |
| Cash Conversion Cycle | -1134.18 | 142.49 | 35.73 | 12.65 | 29.86 |
| Days of Sales Outstanding | 45.28 | 142.49 | 35.73 | 12.65 | 29.86 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 1179.46 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 45.28 | 142.49 | 35.73 | 12.65 | 29.86 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.21 | -0.35 | -0.52 | -0.23 | -0.64 |
| Free Cash Flow Per Share | -0.21 | -0.35 | -0.52 | -0.24 | -0.64 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -356.32 | -85.25 | -69.05 | -5.22 |
| Capital Expenditure Coverage Ratio | 0.00 | -356.32 | -85.25 | -69.05 | -83.48 |
| Operating Cash Flow Coverage Ratio | -9.46 | -10.60 | -9.85 | -2.82 | -3.57 |
| Operating Cash Flow to Sales Ratio | -2.81 | -10.51 | -4.74 | -0.91 | -6.15 |
| Free Cash Flow Yield | -4.30% | -10.71% | -20.96% | -10.20% | -16.54% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -28.29 | -8.61 | -5.70 | -5.06 | -5.42 |
| Price-to-Sales (P/S) Ratio | 65.44 | 98.35 | 22.87 | 9.01 | 37.61 |
| Price-to-Book (P/B) Ratio | 12.04 | 6.23 | 3.91 | 2.57 | 2.44 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -23.25 | -9.33 | -4.77 | -9.81 | -6.05 |
| Price-to-Operating Cash Flow Ratio | -23.25 | -9.36 | -4.83 | -9.95 | -6.12 |
| Price-to-Earnings Growth (PEG) Ratio | 0.51 | 0.63 | 1.31 | 0.14 | 0.36 |
| Enterprise Value Multiple | -27.47 | -8.43 | -5.60 | -5.39 | -4.51 |
| Enterprise Value | 907.77M | 576.73M | 397.34M | 333.46M | 322.91M |
| EV to EBITDA | -27.47 | -8.43 | -5.60 | -5.39 | -4.51 |
| EV to Sales | 64.46 | 93.46 | 21.90 | 8.55 | 29.39 |
| EV to Free Cash Flow | -22.90 | -8.87 | -4.57 | -9.30 | -4.72 |
| EV to Operating Cash Flow | -22.90 | -8.89 | -4.62 | -9.43 | -4.78 |
| Tangible Book Value Per Share | 0.40 | 0.52 | 0.64 | 0.91 | 1.59 |
| Shareholders’ Equity Per Share | 0.40 | 0.52 | 0.64 | 0.91 | 1.59 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | -0.07 | 0.00 |
| Revenue Per Share | 0.07 | 0.03 | 0.11 | 0.26 | 0.10 |
| Net Income Per Share | -0.17 | -0.38 | -0.44 | -0.46 | -0.72 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.07 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.01 | 1.03 | 1.04 |
| Research & Development to Revenue | 1.79 | 8.76 | 4.06 | 2.16 | 5.96 |
| SG&A to Revenue | 1.13 | 3.58 | 1.24 | 0.46 | 1.56 |
| Stock-Based Compensation to Revenue | 0.49 | 1.46 | 0.51 | 0.18 | 0.58 |
| Income Quality | 1.18 | 0.93 | 1.18 | 0.51 | 0.89 |
Currency in USD
